VUF11207 (fumarate)

VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation[1].

Product Specifications

CAS Number

[1785665-61-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vuf11207-fumarate.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C(CN(C(C1=CC(OC)=C(C(OC)=C1)OC)=O)CCC2N(CCC2)C)=C\C3=C(C=CC=C3)F.OC(/C=C/C(O)=O)=O

Molecular Formula

C31H39FN2O8

Molecular Weight

586.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92.|[2]Nugraha AP, et al. C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep. 2022 Mar;25 (3) :78.